nach oben

Erschienen in:

15.09.2017 | Review

Clinical high risk for psychosis in children and adolescents: a systematic review

verfasst von: Jordina Tor, Montserrat Dolz, Anna Sintes, Daniel Muñoz, Marta Pardo, Elena de la Serna, Olga Puig, Gisela Sugranyes, Inmaculada Baeza

Erschienen in: European Child & Adolescent Psychiatry | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

The concept of being at risk for psychosis has been introduced both for adults and children and adolescents, but fewer studies have been conducted in the latter population. The aim of this study is to systematically review the articles associated with clinical description, interventions, outcome and other areas in children and adolescents at risk for psychosis. We searched in MEDLINE/PubMed and PsycINFO databases for articles published up to 30/06/16. Reviewed articles were prospective studies; written in English; original articles with Clinical High Risk (CHR) for psychosis samples; and mean age of samples younger than 18 years. From 103 studies initially selected, 48 met inclusion criteria and were systematically reviewed. Studies show that CHR children and adolescents present several clinical characteristics at baseline, with most attenuated positive-symptom inclusion criteria observed, reporting mostly perceptual abnormalities and suspiciousness, and presenting comorbid conditions such as depressive and anxiety disorders. CHR children and adolescents show lower general intelligence and no structural brain changes compared with controls. Original articles reviewed show rates of conversion to psychosis between 17 and 20% at 1 year follow-up and between 7 and 21% at 2 years. While 36% of patients recovered from their CHR status at 6-year follow-up, 40% still met CHR criteria. Studies in children and adolescents with CHR were conducted with different methodologies, assessments tools and small samples. It is important to conduct studies on psychopharmacological and psychological treatment, as well as replication of the few studies found.

Perälä J, Suvisaari J, Saarni SI et al (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64:19–28. doi:10.1001/archpsyc.64.1.19 CrossRefPubMed

Wittchen HU, Jacobi F, Rehm J et al (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655–679. doi:10.1016/j.euroneuro.2011.07.018 CrossRefPubMed

Mathers C, Ma Fat D, Boerma T, World Health Organization (2004) The global burden of disease: 2004 update. World Health Organization, Geneva

McGorry PD, Killackey E, Yung A (2008) Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry 7:148–156CrossRefPubMedPubMedCentral

Miller PM, Byrne M, Hodges A et al (2002) Childhood behaviour, psychotic symptoms and psychosis onset in young people at high risk of schizophrenia: early findings from the edinburgh high risk study. Psychol Med 32:173–179. doi:10.1017/S0033291701004779 CrossRefPubMed

Cornblatt BA, Lencz T, Smith CW et al (2003) The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull 29:633–651CrossRefPubMed

Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 58:158–164. doi:10.1016/S0924-9338(99)80046-7 CrossRefPubMed

Correll CU, Hauser M, Auther AM, Cornblatt BA (2010) Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry 51:390–431. doi:10.1111/j.1469-7610.2010.02235.x CrossRefPubMedPubMedCentral

Fusar-poli P, Bonoldi I, Yung AR et al (2012) Predicting psychosis. Arch Gen Psychiatry 69:220–229CrossRefPubMed

10.

Arango C (2011) Attenuated psychotic symptoms syndrome: how it may affect child and adolescent psychiatry. Eur Child Adolesc Psychiatry 20:67–70. doi:10.1007/s00787-010-0144-2 CrossRefPubMed

11.

Amminger GP, Schäfer MR, Papageorgiou K et al (2010) Long-Chain ω-3 fatty acids for indicated prevention of psychotic disorders a randomize, placebo-controlled trial. Arch Gen Psychiatry 67:146–154CrossRefPubMed

12.

Schultze-Lutter F, Michel C, Schmidt SJ et al (2015) EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry 30:405–416. doi:10.1016/j.eurpsy.2015.01.010 CrossRefPubMed

13.

Basso MR, Nasrallah HA, Olson SC, Bornstein RA (1997) Cognitive deficits distinguish patients with adolescent- and adult-onset schizophrenia. Neuropsychiatry Neuropsychol Behav Neurol 10:107–112PubMed

14.

Joa I, Johannessen JO, Langeveld J et al (2009) Baseline profiles of adolescent vs. adult-onset first-episode psychosis in an early detection program. Acta Psychiatr Scand 119:494–500. doi:10.1111/j.1600-0447.2008.01338.x CrossRefPubMed

15.

Ballageer T, Malla A, Manchanda R et al (2005) Is adolescent-onset first-episode psychosis different from adult onset? J Am Acad Child Adolesc Psychiatry 44:782–789. doi:10.1097/01.chi.0000164591.55942.ea CrossRefPubMed

16.

Schimmelmann B, Walger P, Schultze-Lutter F (2013) The significance of at-risk symptoms for psychosis in children and adolescents. Can J Psychiatry 58:32–40CrossRefPubMed

17.

Moher D, Hopewell S, Schulz KF et al (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340:c869. doi:10.1136/bmj.c869 CrossRefPubMedPubMedCentral

18.

Miller TJ, McGlashan TH, Rosen JL et al (2003) Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 29:703–715CrossRefPubMed

19.

Welsh P, Tiffin PA (2014) The “at-risk mental state” for psychosis in adolescents: clinical presentation, transition and remission. Child Psychiatry Hum Dev 45:90–98. doi:10.1007/s10578-013-0380-z CrossRefPubMed

20.

Ziermans T, Schothorst P, Magnée M et al (2011) Reduced prepulse inhibition in adolescents at risk for psychosis: a 2-year follow-up study. J Psychiatry Neurosci 36:127–134. doi:10.1503/jpn.100063 CrossRefPubMedPubMedCentral

21.

van Rijn S, Aleman A, de Sonneville L et al (2011) Misattribution of facial expressions of emotion in adolescents at increased risk of psychosis: the role of inhibitory control. Psychol Med 41:499–508. doi:10.1017/S0033291710000929 CrossRefPubMed

22.

Golembo-Smith S, Bachman P, Senturk D et al (2014) Youth-caregiver agreement on clinical high-risk symptoms of psychosis. J Abnorm Child Psychol 42:649–658CrossRefPubMedPubMedCentral

23.

Ziermans T, de Wit S, Schothorst P et al (2014) Neurocognitive and clinical predictors of long-term outcome in adolescents at ultra-high risk for psychosis: a 6-year follow-up. PLoS One 9:e93994. doi:10.1371/journal.pone.0093994 CrossRefPubMedPubMedCentral

24.

Woodberry KA, Seidman LJ, Giuliano AJ et al (2010) Neuropsychological profiles in individuals at clinical high risk for psychosis: relationship to psychosis and intelligence. Schizophr Res 123:188–198. doi:10.1016/j.schres.2010.06.021 CrossRefPubMedPubMedCentral

25.

Armando M, Pontillo M, De CF et al (2015) Twelve-month psychosis-predictive value of the ultra-high risk criteria in children and adolescents. Schizophr Res 169:186–192. doi:10.1016/j.schres.2015.10.033 CrossRefPubMed

26.

Spada G, Pistone SMC, Mcguire MCP (2016) Identifying children and adolescents at ultra high risk of psychosis in Italian neuropsychiatry services: a feasibility study. Eur Child Adolesc Psychiatry. doi:10.1007/s00787-015-0710-8 PubMedCrossRef

27.

Meyer SE, Bearden CE, Lux SR et al (2005) The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J Child Adolesc Psychopharmacol 15:434–451CrossRefPubMed

28.

Ziermans TB, Schothorst PF, Sprong M, van Engeland H (2011) Transition and remission in adolescents at ultra-high risk for psychosis. Schizophr Res 126:58–64. doi:10.1016/j.schres.2010.10.022 CrossRefPubMed

29.

De Wit S, Schothorst PF, Oranje B et al (2014) Adolescents at ultra-high risk for psychosis: long-term outcome of individuals who recover from their at-risk state. Eur Neuropsychopharmacol 24:865–873. doi:10.1016/j.euroneuro.2014.02.008 CrossRefPubMed

30.

Miller TJ, Mcglashan TH et al (1999) Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 19:863–865

31.

Yung AR, Yuen HP, McGorry PD et al (2005) Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry 39:964–971. doi:10.1111/j.1440-1614.2005.01714.x CrossRefPubMed

32.

Amminger GP, Chanen AM, Ohmann S et al (2013) Omega-3 fatty acid supplementation in adolescents with borderline. Can J Psychiatry 58:402–408CrossRefPubMed

33.

Mossaheb N, Schäfer MR, Schlögelhofer M et al (2013) Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective? Schizophr Res 148:163–167. doi:10.1016/j.schres.2013.05.027 CrossRefPubMed

34.

Bartholomeusz CF, Whittle SL, Pilioussis E et al (2014) Relationship between amygdala volume and emotion recognition in adolescents at ultra-high risk for psychosis. Psychiatry Res 224:159–167. doi:10.1016/j.pscychresns.2014.10.005 CrossRefPubMed

35.

Fux L, Walger P, Schimmelmann BG, Schultze-Lutter F (2013) The schizophrenia proneness instrument, child and youth version (SPI-CY): practicability and discriminative validity. Schizophr Res 146:69–78. doi:10.1016/j.schres.2013.02.014 CrossRefPubMed

36.

Kline E, Wilson C, Ereshefsky S et al (2012) Psychosis risk screening in youth: a validation study of three self-report measures of attenuated psychosis symptoms. Schizophr Res 141:72–77. doi:10.1016/j.schres.2012.07.022 CrossRefPubMed

37.

Loewy RL, Pearson R, Vinogradov S et al (2011) Psychosis risk screening with the Prodromal Questionnaire–brief version (PQ-B). Schizophr Res 129:42–46. doi:10.1016/j.schres.2011.03.029 CrossRefPubMedPubMedCentral

38.

Ord LM, Myles-Worsley M, Blailes F, Ngiralmau H (2004) Screening for prodromal adolescents in an isolated high-risk population. Schizophr Res 71:507–508. doi:10.1016/j.schres.2004.03.014 CrossRefPubMed

39.

Miller TJ, Cicchetti D, Markovich PJ et al (2004) The SIPS screen: a brief self-report to detect the schizophrenia prodrome. Schizophr Res 70:78

40.

Thompson E, Kline E, Reeves G, et al (2013) Identifying youth at risk for psychosis using the behavior assessment system for children, Second Edition. Schizophr Res 151:238–44. doi:10.1016/j.schres.2013.09.022

41.

Reynolds CR, Kamphaus RW (2004) Behavior assessment system for children, 2nd edn. American Guidance Service, Circle Pine, MN

42.

Simeonova DI, Nguyen T, Walker EF (2014) Psychosis risk screening in clinical high-risk adolescents: a longitudinal investigation using the Child Behavior Checklist. Schizophr Res 159:7–13. doi:10.1016/j.schres.2014.07.046 CrossRefPubMedPubMedCentral

43.

Simeonova DI, Attalla A, Trotman H et al (2011) Does a parent-report measure of behavioral problems enhance prediction of conversion to psychosis in clinical high-risk adolescents? Schizophr Res 130:157–163. doi:10.1016/j.schres.2011.03.034.Does CrossRefPubMedPubMedCentral

44.

Kline E, Thompson E, Schimunek C et al (2013) Parent-adolescent agreement on psychosis risk symptoms. Schizophr Res 147:147–152. doi:10.1016/j.schres.2013.03.007 CrossRefPubMed

45.

Thompson E, Kline E, Reeves G, Pitts Steven C, Bussell K, Schiffman J (2014) Using parent and youth reports from the behavior assessment system for children, second edition to identify individuals at clinical high-risk for psychosis. Schizophr Res 154(1-3):107–112. doi:10.1016/j.schres.2014.02.009 CrossRefPubMed

46.

Bearden CE, Wu KN, Caplan R, Cannon TD (2011) Thought disorder and communication deviance as predictors of outcome in youth at clinical high risk for psychosis. J Am Acad Child Adolesc Psychiatry 50:669–680. doi:10.1016/j.biotechadv.2011.08.021.Secreted CrossRefPubMedPubMedCentral

47.

Correll CU, Smith CW, Auther AM et al (2008) Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. J Child Adolesc Psychopharmacol 18:475–490. doi:10.1089/cap.2007.110 CrossRefPubMedPubMedCentral

48.

Ziermans TB, Schothorst PF, Sprong M et al (2012) Reduced prepulse inhibition as an early vulnerability marker of the psychosis prodrome in adolescence. Schizophr Res 134:10–15. doi:10.1016/j.schres.2011.10.009 CrossRefPubMed

49.

Rapado-Castro M, McGorry PD, Yung A et al (2015) Sources of clinical distress in young people at ultra high risk of psychosis. Schizophr Res 165:15–21. doi:10.1016/j.schres.2015.03.022 CrossRefPubMed

50.

Thompson E, Kline E, Ellman LM et al (2015) Emotional and behavioral symptomatology reported by help-seeking youth at clinical high-risk for psychosis. Schizophr Res 162:79–85. doi:10.1016/j.schres.2015.01.023 CrossRefPubMed

51.

Gerstenberg M, Hauser M, Al-Jadiri A et al (2015) Focus on childhood and adolescent mental health frequency and correlates of DSM-5 attenuated psychosis syndrome in a sample of adolescent inpatients with nonpsychotic psychiatric disorders. J Clin Psychiatry. doi:10.4088/JCP.14m09435 CrossRefPubMed

52.

Lo CN, Saba R, Hauser M et al (2016) Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. Eur Child Adolesc Psychiatry. doi:10.1007/s00787-016-0832-7 CrossRef

53.

Nitka F, Richter J, Parzer P et al (2016) Health-related quality of life among adolescents: a comparison between subjects at ultra-high risk for psychosis and healthy controls. Psychiatry Res 235:110–115. doi:10.1016/j.psychres.2015.11.040 CrossRefPubMed

54.

van Rijn S, Aleman A, de Sonneville L et al (2011) Neuroendocrine markers of high risk for psychosis: salivary testosterone in adolescent boys with prodromal symptoms. Psychol Med 41:1815–1822. doi:10.1017/S0033291710002576 CrossRefPubMed

55.

Simeonova DI, Lee FJ, Walker EF (2015) Longitudinal investigation of the relationship between family history of psychosis and affective disorders and Child Behavior Checklist ratings in clinical high-risk adolescents. Schizophr Res 166:24–30. doi:10.1016/j.schres.2015.04.027 CrossRefPubMedPubMedCentral

56.

Auther AM, McLaughlin D, Carrión RE et al (2012) Prospective study of cannabis use in adolescents at clinical high-risk for psychosis: impact on conversion to psychosis and functional outcome. Psychol Med 42:2485–2497. doi:10.1017/S0033291712000803.Prospective CrossRefPubMedPubMedCentral

57.

Woodberry KA, McFarlane WR, Giuliano AJ et al (2013) Change in neuropsychological functioning over one year in youth at clinical high risk for psychosis. Schizophr Res 146:87–94. doi:10.1016/j.schres.2013.01.017 CrossRefPubMedPubMedCentral

58.

Berger GE, Smesny S, Schäfer MR et al (2016) Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis. PLoS One 2:1–17. doi:10.1371/journal.pone.0148429 CrossRef

59.

O’Brien MP, Gordon JL, Bearden CE et al (2006) Positive family environment predicts improvement in symptoms and social functioning among adolescents at imminent risk for onset of psychosis. Schizophr Res 81:269–275. doi:10.1016/j.schres.2005.10.005 CrossRefPubMed

60.

O’Brien MP, Zinberg JL, Bearden CE et al (2008) Parent attitudes and parent adolescent interaction in families of youth at risk for psychosis and with recent-onset psychotic symptoms. Early Interv Psychiatry 2:268–276. doi:10.1111/j.1751-7893.2008.00088.x CrossRefPubMed

61.

O’Brien MP, Zinberg JL, Ho L et al (2009) Family problem solving interactions and 6-month symptomatic and functional outcomes in youth at ultra-high risk for psychosis and with recent onset psychotic symptoms: a longitudinal study. Schizophr Res 107:198–205. doi:10.1016/j.schres.2008.10.008 CrossRefPubMed

62.

Ziermans TB, Durston S, Sprong M et al (2009) No evidence for structural brain changes in young adolescents at ultra high risk for psychosis. Schizophr Res 112:1–6. doi:10.1016/j.schres.2009.04.013 CrossRefPubMed

63.

Welsh P, Cartwright-Hatton S, Wells A et al (2014) Metacognitive beliefs in adolescents with an at-risk mental state for psychosis. Early Interv Psychiatry 8:82–86. doi:10.1111/eip.12052 CrossRefPubMed

64.

Bowie CR, McLaughlin D, Carrión RE et al (2012) Cognitive changes following antidepressant or antipsychotic treatment in adolescents at clinical risk for psychosis. Schizophr Res 137:110–117. doi:10.1016/j.schres.2012.02.008 CrossRefPubMedPubMedCentral

65.

Buchy L, Stowkowy J, MacMaster FP et al (2015) Meta-cognition is associated with cortical thickness in youth at clinical high risk of psychosis. Psychiatry Res Neuroimaging 233:418–423. doi:10.1016/j.pscychresns.2015.07.010 CrossRef

66.

Mittal VA, Daley M, Shiode MF et al (2010) Striatal volumes and dyskinetic movements in youth at high-risk for psychosis. Schizophr Res 123:68–70. doi:10.1016/j.schres.2010.08.002 CrossRefPubMedPubMedCentral

67.

Karlsgodt KH, van Erp TGM, Bearden CE, Cannon TD (2014) Altered relationships between age and functional brain activation in adolescents at clinical high risk for psychosis. Psychiatry Res Neuroimaging 221:21–29. doi:10.1016/j.pscychresns.2013.08.004 CrossRef

68.

Gonzalez-Heydrich J, Bosquet Enlow M, D’Angelo E et al (2015) Early auditory processing evoked potentials (N100) show a continuum of blunting from clinical high risk to psychosis in a pediatric sample. Schizophr Res 169:340–345. doi:10.1016/j.schres.2015.10.037 CrossRefPubMedPubMedCentral

69.

Corcoran CM, Smith C, McLaughlin D et al (2012) HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia. Schizophr Res 135:170–174. doi:10.1016/j.schres.2011.11.035 CrossRefPubMedPubMedCentral

70.

Schmidt SJ, Schultze-Lutter F, Schimmelmann BG et al (2015) EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 30:388–404. doi:10.1016/j.eurpsy.2015.01.013 CrossRefPubMed

71.

van Rijn S, Schothorst P, van’t Wout M et al (2011) Affective dysfunctions in adolescents at risk for psychosis: emotion awareness and social functioning. Psychiatry Res 187:100–105. doi:10.1016/j.psychres.2010.10.007 CrossRefPubMed

72.

O’Brien MP, Zinberg JL, Bearden CE et al (2007) Psychoeducational multi-family group treatment with adolescents at high risk for developing psychosis. Early Interv Psychiatry 1:325–332. doi:10.1111/j.1751-7893.2007.00046.x CrossRefPubMed

73.

Miklowitz DJ, O’Brien MP, Schlosser DA et al (2014) Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry 53:848–858. doi:10.1016/j.jaac.2014.04.020 CrossRefPubMedPubMedCentral

74.

Scott J, Martin G, Bor W et al (2009) The prevalence and correlates of hallucinations in Australian adolescents: results from a national survey. Schizophr Res 107:179–185. doi:10.1016/j.schres.2008.11.002 CrossRefPubMed

75.

Yung AR, Nelson B, Baker K et al (2009) Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia. Aust New Zeal J Psychiatry 43:118–128. doi:10.1080/00048670802607188 CrossRef

76.

Schultze-Lutter F, Renner F, Paruch J et al (2014) Self-reported psychotic-like experiences are a poor estimate of clinician-rated attenuated and frank delusions and hallucinations. Psychopathology 47:194–201. doi:10.1159/000355554 CrossRefPubMed

77.

Michel C, Kutschal C, Schimmelmann BG, Schultze-Lutter F (2016) Convergent and concurrent validity of the Frankfurt Complaint Questionnaire as a screener for psychosis risk. J Risk Res. doi:10.1080/13669877.2016.1179209 CrossRef

78.

Michel C, Schultze-Lutter F, Schimmelmann BG (2014) Screening instruments in child and adolescent psychiatry: general and methodological considerations. Eur Child Adolesc Psychiatry 23:725–727. doi:10.1007/s00787-014-0608-x CrossRefPubMed

79.

Schimmelmann BG, Michel C, Martz-Irngartinger A et al (2015) Age matters in the prevalence and clinical significance of ultra-high-risk for psychosis symptoms and criteria in the general population: findings from the BEAR and BEARS-kid studies. World Psychiatry 14:189–197. doi:10.1002/wps.20216 CrossRefPubMedPubMedCentral

80.

Schultze-Lutter F, Hubl D, Schimmelmann BG, Michel C (2017) Age effect on prevalence of ultra-high risk for psychosis symptoms: replication in a clinical sample of an early detection of psychosis service. Eur Child Adolesc Psychiatry. doi:10.1007/s00787-017-0994-y PubMedCrossRef

81.

Armando M, Schneider M, Pontillo M et al (2017) No age effect in the prevalence and clinical significance of ultra-high risk symptoms and criteria for psychosis in 22q11 deletion syndrome: confirmation of the genetically driven risk for psychosis? PLoS One 12:e0174797. doi:10.1371/journal.pone.0174797 CrossRefPubMedPubMedCentral

82.

Fusar-Poli P, Nelson B, Valmaggia L et al (2014) Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull 40:120–131. doi:10.1093/schbul/sbs136 CrossRefPubMed

83.

Fusar-Poli P, Cappucciati M, Borgwardt S et al (2016) Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk. JAMA Psychiatry 73(2):113–120. doi:10.1001/jamapsychiatry.2015.2324 CrossRefPubMed

84.

Cannon TD, Cadenhead K, Cornblatt B et al (2008) Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 65:28–37. doi:10.1001/archgenpsychiatry.2007.3 CrossRefPubMedPubMedCentral

85.

Yung AR, Yuen HP, Berger G et al (2007) Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 33:673–681. doi:10.1093/schbul/sbm015 CrossRefPubMedPubMedCentral

86.

Werbeloff N, Drukker M, Dohrenwend BP et al (2012) Self-reported attenuated psychotic symptoms as forerunners of severe mental disorders later in life. Arch Gen Psychiatry 69:467–475. doi:10.1001/archgenpsychiatry.2011.1580 CrossRefPubMed

87.

Kelleher I, Murtagh A, Molloy C et al (2012) Identification and characterization of prodromal risk syndromes in young adolescents in the community: a population-based clinical interview study. Schizophr Bull 38:239–246. doi:10.1093/schbul/sbr164 CrossRefPubMed

88.

Addington J, Heinssen R (2012) Prediction and prevention of psychosis in youth at clinical high risk. Annu Rev Clin Psychol 8:269–289. doi:10.1146/annurev-clinpsy-032511-143146 CrossRefPubMed

89.

Tiffin PA, Welsh P (2013) Practitioner review: schizophrenia spectrum disorders and the at-risk mental state for psychosis in children and adolescents—evidence-based management approaches. J Child Psychol Psychiatry Allied Discip 54:1155–1175. doi:10.1111/jcpp.12136 CrossRef

90.

Fusar-Poli P, Deste G, Smieskova R et al (2012) Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 69:562–571. doi:10.1001/archgenpsychiatry.2011.1592 PubMedCrossRef

91.

Lencz T, Smith CW, Auther AM, Correll CU, Cornblatt B (2003) The assessment of “prodromal schizophrenia”: unresolved issues and further directions. Schizophr Bull 29(4):717–728CrossRefPubMed

Titel: Clinical high risk for psychosis in children and adolescents: a systematic review
verfasst von: Jordina Tor
Montserrat Dolz
Anna Sintes
Daniel Muñoz
Marta Pardo
Elena de la Serna
Olga Puig
Gisela Sugranyes
Inmaculada Baeza
Publikationsdatum: 15.09.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Child & Adolescent Psychiatry / Ausgabe 6/2018
Print ISSN: 1018-8827
Elektronische ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-017-1046-3

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Clinical high risk for psychosis in children and adolescents: a systematic review

Abstract

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Typ-2-Diabetes und Depression folgen oft aufeinander

Darf man die Behandlung eines Neonazis ablehnen?

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

Update Psychiatrie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Cortical dysplasia and autistic trait severity in children with Tuberous Sclerosis Complex: a clinical epidemiological study

Peer status in relation to psychotic experiences and psychosocial problems in adolescents: a longitudinal school-based study

Trauma exposure in children with and without ADHD: prevalence and functional impairment in a community-based study of 6–8-year-old Australian children

Predictive validity of a service-setting-based measure to identify infancy mental health problems: a population-based cohort study

Self-reported mental health in children ages 6–12 years across eight European countries

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Typ-2-Diabetes und Depression folgen oft aufeinander

Darf man die Behandlung eines Neonazis ablehnen?

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

Update Psychiatrie